Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Weather forecasters warn Pakistanis to stay indoors ahead of new heat wave
Alibaba returns to simple and agile structure
Midwest storms: Large hail, torrential rain and tornadoes and more is coming
China's foreign trade hits record high in Q1
Xinhua Headlines: Xi Attends SCO Summit, Calls for Unity, Coordination
Teenagers in pastoral areas of Tibet attend taekwondo camp
EU seals a deal on using profits from frozen Russian assets to help arm Ukraine
Teenagers in pastoral areas of Tibet attend taekwondo camp